A practical reference on mass spectrometry: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-02. Anything still debated is marked as such rather than presented as settled.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
| Property | Value | Notes |
|---|---|---|
| Detection wavelength | 214 nm | Peptide bond absorption; 280 nm is not useful. |
| Confirmatory method | Electrospray mass spectrometry | Verifies mass near 3108 Da. |
| Solution stability | Limited at room temperature | Aqueous solutions degrade faster than powder. |
| Recommended storage | -20 °C | For lyophilized powder; protect from moisture. |
| Purity criterion | ≥95% by RP-HPLC | Typical research-grade specification. |
== Commercial syntheses of amino acids == Several methods exist to synthesize amino acids aside from the Strecker synthesis. The commercial production of amino acids, however, usually relies on mutant bacteria that overproduce individual amino acids using glucose as a carbon source. Otherwise amino acids are produced by enzymatic conversions of synthetic intermediates. 2-Aminothiazoline-4-carboxylic acid is an intermediate in one industrial synthesis of L-cysteine. Aspartic acid is produced by the addition of ammonia to fumarate using a lyase.
=== EC 2.7.6: Diphosphotransferases === EC 2.7.6.1: ribose-phosphate diphosphokinase EC 2.7.6.2: thiamine diphosphokinase EC 2.7.6.3: 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine diphosphokinase EC 2.7.6.4: nucleotide diphosphokinase EC 2.7.6.5: GTP diphosphokinase
== History and preparation == Graphite oxide was first prepared by Oxford chemist Benjamin C. Brodie in 1859 by treating graphite with a mixture of potassium chlorate (KClO3) and fuming nitric acid (HNO3). He reported synthesis of "paper-like foils" with 0.05 mm thickness. In 1957, Hummers and Offeman developed a safer, quicker, and more efficient process called Hummers' method, using a mixture of sulfuric acid (H2SO4), sodium nitrate (NaNO3), and potassium permanganate (KMnO4), which is still widely used, often with some modifications. Largest monolayer GO with highly intact carbon framework and minimal residual impurity concentrations can be synthesized in inert containers using highly pure reactants and solvents. Graphite oxides exhibit considerable variation in properties with oxidation degree and synthesis method. For example, the temperature point of explosive exfoliation is generally higher for graphite oxide prepared by the Brodie method compared to Hummers graphite oxide, the difference is up to 100 degrees with the same heating rates. The hydration and solvation properties of Brodie and Hummers graphite oxides are also remarkably different. Recently a mixture of H2SO4 and KMnO4 has been used to cut open carbon nanotubes lengthwise, resulting in microscopic flat ribbons of graphene, a few atoms wide, with the edges "capped" by oxygen atoms (=O) or hydroxyl groups (–OH).
== Biological function == Prolyl hydroxylase catalyzes the formation of hydroxyproline. The modification has a significant impact on the stability of collagen, the major connective tissue of the human body. Specifically, hydroxylation increases the melting temperature (Tm) of helical collagen by 16 °C, as compared to unhydroxylated collagen, a difference that allows the protein to be stable at body temperature. Due to the abundance of collagen (about one third of total protein) in humans, and the high occurrence of this modification in collagen, hydroxyproline is quantitatively the most abundant post-translational modification in humans. The enzyme acts specifically on proline contained within the X-Pro-Gly motif – where Pro is proline. Because of this motif-specific behavior, the enzyme also acts on other proteins that contain this same sequence. Such proteins include C1q, elastins, PrP, Argonaute 2, and conotoxins, among others.
Sources: en.wikipedia.org
== History == The safety and effectiveness of dulaglutide were evaluated in six clinical trials in which 3,342 subjects with type 2 diabetes received dulaglutide. Subjects receiving dulaglutide had an improvement in their blood sugar control as observed with reductions in HbA1c level (hemoglobin A1c is a measure of blood sugar control). The US Food and Drug Administration (FDA) approved dulaglutide with a Risk Evaluation and Mitigation Strategy (REMS), and granted the approval of Trulicity to Eli Lilly and Company. The REMS consists of a number of steps that Eli Lilly will take to make physicians aware of the risk of pancreatitis and the potential risk of medullary thyroid carcinoma associated with the drug. In 2020, the FDA approved two higher doses of the medication, 3.0 mg and 4.5 mg, based on results of the AWARD-11 trial demonstrating improved glucose lowering and weight benefits.
Dòugān (豆乾, literally "dry tofu" in Chinese) is an extra firm variety of tofu where a large proportion of the liquid has been pressed out. Dòugān contains the least moisture of all fresh tofu, the firmness of fully cooked meat, and a somewhat rubbery feel similar to that of paneer. It is not easily crumbled except when sliced thinly. Some varieties of dougan has the pattern of the muslin used to drain and press it. Western firm tofu is milled and reformed after pressing. One way to cook dougan is to cut it into thin slices called shredded dried tofu (乾絲, gānsī). The strings look like loose cooked noodles and can be served cold, stir-fried, or added to soup, as with Japanese aburaage.
== pKa calculation methods == Several software packages and webserver are available for the calculation of protein pKa values. Note that the pKHHa value does in general depend on the pH value. This dependence is small for weakly interacting groups like well solvated amino acid side chains on the protein surface, but can be large for strongly interacting groups like those buried in enzyme active sites or integral membrane proteins. While many protein pKa prediction methods are available, their accuracies often differ significantly due to subtle and often drastic differences in strategy.
Sources: en.wikipedia.org
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.
The lyophilized powder is usually stored at -20 °C or below. Dissolved solutions are less stable and should be prepared fresh when possible. Freeze-thaw cycling can reduce integrity.
It lacks aromatic residues, so it does not absorb strongly at 280 nm. Its negative charge and hydrophilic nature can affect chromatographic retention. These properties require method development for reliable separation.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.